Sodium-Glucose Transporter 2
"Sodium-Glucose Transporter 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sodium-glucose transporter that is expressed in the luminal membrane of the PROXIMAL KIDNEY TUBULES.
| Descriptor ID |
D051297
|
| MeSH Number(s) |
D12.776.157.530.450.625.437.750 D12.776.157.530.500.750.750 D12.776.157.530.937.700 D12.776.543.585.450.625.562.750 D12.776.543.585.500.750.750 D12.776.543.585.937.825
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sodium-Glucose Transporter 2".
Below are MeSH descriptors whose meaning is more specific than "Sodium-Glucose Transporter 2".
This graph shows the total number of publications written about "Sodium-Glucose Transporter 2" by people in this website by year, and whether "Sodium-Glucose Transporter 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 3 | 4 |
| 2017 | 4 | 26 | 30 |
| 2018 | 5 | 13 | 18 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Sodium-Glucose Transporter 2" by people in Profiles.
-
Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19. Int J Cardiol. 2021 08 01; 336:123-129.
-
Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. Pulm Pharmacol Ther. 2021 08; 69:102035.
-
Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic. Diabetes Obes Metab. 2021 Jul; 23(7):1696-1700.
-
SGLT2 inhibition during the COVID-19 epidemic: Friend or foe? Diabetes Metab. 2020 10; 46(5):343-344.
-
Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019 12; 170:113677.
-
Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2019; 7(1):e000725.
-
More CREDENCE for SGLT2 Inhibition. Circulation. 2019 10 29; 140(18):1448-1450.
-
[Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME]. Rev Med Liege. 2019 Apr; 74(4):185-191.
-
Sodium-Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus: A Review of Large-Scale Cardiovascular Outcome Studies and Possible Mechanisms of Benefit. Cardiol Rev. 2018 Nov/Dec; 26(6):312-320.
-
Lowering Blood Pressure with the Combination of a Sodium-Glucose Cotransporter 2 Inhibitor and a Glucagon-like Peptide-1 Receptor Agonist in Type 2 Diabetic Patients: A Clinical Evidence. High Blood Press Cardiovasc Prev. 2018 Dec; 25(4):417-420.